CN104027350B - The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine - Google Patents
The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine Download PDFInfo
- Publication number
- CN104027350B CN104027350B CN201410239813.6A CN201410239813A CN104027350B CN 104027350 B CN104027350 B CN 104027350B CN 201410239813 A CN201410239813 A CN 201410239813A CN 104027350 B CN104027350 B CN 104027350B
- Authority
- CN
- China
- Prior art keywords
- hydrogen molecule
- state carrier
- solid
- molecule solid
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine, it is characterized in that, obesity due to hydrogen molecule solid-state carrier is unbalance to diet structure has inhibitory action, described hydrogen molecule solid-state carrier is with calcium, the carbonate of magnesium is main the more than 50% of solid matter content that accounts for, form is Powdered, graininess, the solid-state form of amorphous type, this substance dissolves or be suspended in after liquid, can in solution, discharge the material of hydrogen molecule, in solution, the content of hydrogen is more than 0.1ppm and below saturated concentration, this material comprises but is not only hydrogenation coral calcium, the invention provides the application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine, the in the situation that of normal diet, take in hydrogen molecule solid-state carrier, meet in vivo water by hydrogen molecule solid-state carrier and discharge hydrogen molecule and the diffusion of target different parts, Scavenger of ROS free radical, alleviates oxidative damage and the disease prevention and cure object that reaches.
Description
Technical field
The present invention relates to biology and medicine and pharmacology technical field, particularly hydrogen molecule solid-state carrier suppresses fat in preparationHealth products and medicine in application.
Background technology
Obesity is body fat overheap many with blood sugar, blood fat, dysarteriotony, insulin resistance, chronic inflammationChronic disease, be the diseases occurred frequently such as atherosclerotic, essential hypertension, diabetes B and fatty liver danger because ofElement. Over nearly 30 years, obesity is globalization fashion trend, and nearly all national resident's average weight index is all in continuous increase,Within 2008, global Overweight and obesity is grown up respectively up to 14.6 hundred million and 500,000,000, has become the key factor that affects whole mankind's health.
Along with the raising of people's living standard in recent years and the change of habits and customs, the food of higher fatty acid high heat is tied at dietIn structure, continue to increase, more many seats are few moving simultaneously, and the problem that causes fat constantly highlights. Due to current causing a disease for this problemMechanism is not yet completely clear and definite, lacks and improves effective methods for the treatment of, the feelings that make high fat diet be difficult to avoid at factors simultaneouslyUnder condition, the method for preventing and treating of trying to explore effectively to alleviate the problem such as obesity, fatty liver of diet structure due to unbalance has importantMeaning. Existing large quantity research shows to cause fat when long term high-fat diet, and makes liver fat transship, occur glycolipid metabolism obstacleTime, liver and other organ are in oxidative stress, energy metabolism impairment state and a large amount of active oxygens that produce are to cause tissueThe major reason of the further damage of cell.
The biological study of hydrogen thinks that hydrogen is a kind of weak reductant, can in living things system, selectively suppress with hydroxyl freelyThe stronger free radical of destructiveness that base, peroxynitrite are representative. Meanwhile, hydrogen is small-molecule substance, is easy at bodyInterior free diffusing, can cross the human body barriers that many medicines cannot be crossed, and arrives the advantage of focus. Current existing research tableBright, take in mode with specific hydrogen molecule, as rich hydrogen water or rich hydrogen physiological saline etc., can significantly alleviate taking oxidative damage as general characterThe course advancement of disease model.
Hydrogen molecule solid-state carrier can be slowly in water, Stable Release hydrogen, with common hydrogen absorption method as rich hydrogen water,Rich hydrogen physiological saline etc. is compared, and the hydrogen slowly releasing effect of hydrogen molecule solid-state carrier is with the obvious advantage. Hydrogen based on rich hydrogen liquid dissipatesProblem, takes in hydrogen molecule solid-state carrier and is more conducive to hydrogen molecule arrival focus performance physiological effect.
Summary of the invention
The object of the present invention is to provide hydrogen molecule solid-state carrier answering in the fat health products of preparation inhibition and medicineWith, the in the situation that of normal diet, take in hydrogen molecule solid-state carrier, meet in vivo water release hydrogen by hydrogen molecule solid-state carrier and divideThe diffusion of son and target different parts, Scavenger of ROS free radical, alleviates oxidative damage and the disease prevention and cure object that reaches.
In order to achieve the above object, the technical solution adopted in the present invention is:
The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine, is characterized in that hydrogen moleculeObesity due to solid-state carrier is unbalance to diet structure has inhibitory action, and described hydrogen molecule solid-state carrier is with calcium, magnesiumCarbonate be main the more than 50% of solid matter content that accounts for, form is the solid-state shape of Powdered, graininess, amorphous typeFormula, this substance dissolves or be suspended in after liquid can discharge the material of hydrogen molecule in solution, and in solution, the content of hydrogen is0.1ppm is above and below saturated concentration, this material comprises but is not only hydrogenation coral calcium.
Inhibiting effective absorption concentration range that hydrogen molecule solid-state carrier occurs obesity is per kilogram of body weight every day10-50 milligram.
The body weight that hydrogen molecule solid-state carrier can effectively improve in fat generating process increases.
Hydrogen molecule solid-state carrier can effectively improve the Fat Accumulation in fat generating process.
Hydrogen molecule solid-state carrier can effectively improve the generation of the disorders of lipid metabolism in fat generating process.
Hydrogen molecule solid-state carrier can effectively improve the generation that the liver fat in fat generating process becomes.
Hydrogen molecule solid-state carrier can effectively improve the generation of the fat hepatitis in fat generating process.
Hydrogen molecule solid-state carrier can effectively reduce content of triglyceride in blood.
Hydrogen molecule solid-state carrier can effectively reduce triglycerides in liver and the content of FFA.
Hydrogen molecule solid-state carrier can effectively reduce the inflammatory factor in liver, as TNF, interleukin-6 andThe content of monocyte chemoattractant protein-1.
Major advantage of the present invention is: 1, work out first hydrogen molecule solid-state carrier at the fat health care food occurring of controlIn product and medicine, apply. 2, hydrogen is small-molecule substance, compares other polyphenoils or medicine, is easier to permeate through cell membranes knotStructure, remove free radical and alleviate pathology progress.
Brief description of the drawings
Fig. 1 is the inhibitory action that hydrogenation coral calcium increases the body weight of high fat diet induction. Wherein: abscissa is hydrogenation coralThe absorption concentration of coral calcium, the body weight that ordinate is rat.
Fig. 2 is the epididymal adipose tissues of hydrogenation coral calcium to high fat diet induction and the inhibitory action of perirenal adipose tissue increase,Fig. 2 A is the inhibitory action to epididymal adipose tissues, and Fig. 2 B is the inhibitory action to perirenal fat. Wherein: abscissa is hydrogenation coral calciumAbsorption concentration, the weight that ordinate is rat fat tissue.
Fig. 3 is the inhibitory action that hydrogenation coral calcium rises to the Triglycerides in Serum content of high fat diet induction. Wherein:Abscissa is the absorption concentration of hydrogenation coral calcium, the content that ordinate is Triglycerides in Serum.
Fig. 4 is the inhibitory action of hydrogenation coral calcium to content of triglyceride rising in the liver of high fat diet induction. Wherein:Abscissa is the absorption concentration of hydrogenation coral calcium, and ordinate is the content of triglycerides in liver.
Fig. 5 is the inhibitory action of hydrogenation coral calcium to FFA content rising in the liver of high fat diet induction. ItsIn: abscissa is the absorption concentration of hydrogenation coral calcium, and ordinate is the content of FFA in liver.
Fig. 6 is the inhibitory action of hydrogenation coral calcium to inflammatory factor in the liver of high fat diet induction. Fig. 6 A is to tumourThe inhibitory action of necrosin, Fig. 6 B is the inhibitory action to interleukin-6, Fig. 6 C is pressing down monocyte chemoattractant protein-1Make and use. Wherein: abscissa is the absorption concentration of hydrogenation coral calcium, and ordinate is the content of inflammatory factor in liver.
Detailed description of the invention
Below in conjunction with the drawings and the specific embodiments, the present invention is elaborated.
1. experiment material
Hydrogenation coral calcium (coralcalciumhydride, CCH) is bought from Shanghai Quanren Biotechnology Co., Ltd.;TNF, interleukin-6 enzyme-linked immunosorbent assay kit, triglycerides, FFA is measured kit from southCapital is built up Bioengineering Research Institute and is bought; TRIzol reagent is bought from Invitrogen company; RNA reverse transcription kit, SYBRFrom Dalian, precious biotech firm buys fluorescent dye. RNA primer sequence is ordered and is closed from the prosperous bio tech ltd of Beijing AudioCodesBecome.
2. experimental animal feeding and model are set up
SD male rat is to buy from Shanghai Si Laike animal Co., Ltd. Rat feeding is at controllable temperature (22 degreeTo 28 degree) and the room of humidity (60%) in, the light in room maintains in the circulation at 12 hour daytime, 12 hour night,Middle rat is carried out in experiment can ad lib and water inlet. Experimental rat one is divided into four groups, 12 every group. Four groups are respectively: (1)Normal diet group; (2) high fat diet group (3) high fat diet group simultaneously every day gavage 10mg/kg hydrogenation coral calcium; (4) high fatDiet group simultaneously every day gavage 50mg/kg hydrogenation coral calcium. Be 3 months experimental period.
3. experimental technique
Triglycerides detects
The triglyceride levels of serum and liver all adopts business triglycerides detection kit and enters by detecting descriptionRow is measured.
FFA detects
Adopt liberty of commerce fatyy acids kit and measure by detecting description.
Inflammatory factor detects
Adopt the method for reverse transcription RNA-real-time fluorescence quantitative PCR to detect. Concrete grammar is as follows:
RNA extracts
Get 50mg tissue and add 1mLofTRIzol reagent, with tissue employing ultrasonication, the material that fragmentation is good is put intoIn centrifuge tube, 12,000g, 4 DEG C, centrifugal 10 minutes. Stay supernatant, discard precipitation. Add 200ul chloroform (1/5 cumulative volume) extractingAlbumen, acutely mixes 15 seconds, and room temperature was placed after 15 minutes, 12,000g, 4 DEG C, centrifugal 10 minutes. Upper water phase transfer is extremely anotherIn one Ep pipe, add equal-volume isopropyl alcohol, after mixing, place after 1h for-20 DEG C, 12,000g,, centrifugal 10 minutes, abandons supernatant by 4 DEG C.Add 75% ethanol of 1mL precooling, put upside down and mix, 7500rpm, 4 DEG C, centrifugal 5 minutes. Abandon supernatant, superclean bench is placed30min, vapors away ethanol volatilization completely, is dissolved in 50ulDEPC water. Measure its concentration by UV spectrophotometer measuring,For reverse transcription.
RNA reverse transcription
Transcribing volume is 25ul, take out 2ugRNA, add random primer 0.5ug, be placed in 70 DEG C, 5 minutes, destroy its twoLevel structure. Be placed in immediately on ice afterwards, avoid secondary structure to recover. Add 3uldNTP10mM, 5ul reverse transcription buffer solution (M-MLV5XReactionBuffer), 200 unit reverse transcriptase (M-MLVRT), are supplemented to 25ul volume with DEPC water, incubate for 37 DEG CEducate 60 minutes. Be placed in-20 DEG C for subsequent use.
Real-time fluorescence quantitative PCR (Real-timePCR)
Undertaken by SYBRGreen method, reaction system comprises 1ulcDNA, II, 0.5ul upstream and downstream primer mixed liquor (10uM), adds aqua sterilisa to 10ul. Reaction condition is according to description, and 95 DEG C are unwind10min, carries out 40 cycle P CR (each circulation comprises 95 DEG C of 30s, 55 DEG C of 30s, 72 DEG C of 20s), finally observes melt curve analysis(95 DEG C of 15s, 60 DEG C of 15s, 95 DEG C of 15s). α-tubulin is as internal reference, tests primer sequence used to be: tumor necrosis factorSon, forward:5 '-TCGTAGCAAACCACCAAGCA-3 '
Reverse:5 '-CCCTTGAAGAGAACCTGGGAGTA-3 '; Interleukin-6, forward:5 '-TCCTACCCCAACTTCCAATGCTC-3 ' reverse:5 '-TTGGATGGTCTTGGTCCTTAGCC-3 '; Monocyte chemotacticAlbumen-1, forward:5 '-ATGCAGGTCTCTGTCACGCT-3 ' reverse:5 '-GGTGCTGAAGTCCTTAGGGT-3 ';
α-tubulin，forward:5'–TGCTGCCATTGCCACCATCA-3'reverse:5'-CTCACCCTCACCCTCCACCG-3’。
Statistical analysis
Result represents with Mean ± S.E.M form, and statistics represents the statistics of 9 rats; Data analysis is usedOneWay-ANOVA analytical method, significantly statistical significance is * p < 0.05, * * p < 0.01, * * * p < 0.001.
Embodiment mono-
The inhibitory action that hydrogenation coral calcium increases the body weight of high fat diet induction.
Measure before and after respectively the body weight of rat in experiment, use the rat body weight after experiment finishes to cut realityTest the body weight while beginning, draw the body weight of rat increase in three months. Fig. 1 shows that high fat diet induced the remarkable increase of body weight,Take in the increase that hydrogenation coral calcium can effectively suppress rat body weight.
Embodiment bis-
The epididymal adipose tissues of hydrogenation coral calcium to high fat diet induction and the inhibitory action of perirenal adipose tissue increase.
After experiment finishes, put to death rat, take out epididymal adipose tissues and perirenal fat and weigh, Fig. 2 A and Fig. 2 B show respectively attachedTestis fat and a large amount of accumulation of perirenal fat, and low-fat accumulation can effectively fall in the absorption of hydrogenation coral calcium.
Embodiment tri-
The inhibitory action of the disorders of lipid metabolism of hydrogenation coral calcium to high fat diet induction.
Fig. 3 shows that in high fat diet induction blood, content of triglyceride obviously rises, and the absorption of hydrogenation coral calcium canEffectively reduce the content of triglycerides.
Embodiment tetra-
The inhibitory action that hydrogenation coral calcium becomes the liver fat of high fat diet induction.
Fig. 4 shows that in high fat diet induction liver, content of triglyceride obviously rises, and the absorption of hydrogenation coral calcium canEffectively reduce the content of triglycerides. Fig. 5 shows that in high fat diet induction liver, FFA content obviously rises, and hydrogenationThe absorption of coral calcium can effectively reduce the content of FFA.
Embodiment six
The inhibitory action of the fat hepatitis of hydrogenation coral calcium to high fat diet induction.
Fat hepatitis is the notable feature in NASH pathology generating process, is also pathological diagnosis simultaneouslyGood foundation. Fig. 6 A, Fig. 6 B and Fig. 6 C show respectively TNF, interleukin-6 and monokaryon in high fat diet induction liverCell chemotaxis albumen-1 level obviously rises, and these indexs have all disclosed the non-alcoholic fatty liver disease pathology of high fat diet inductionIn evolution, follow inflammatory reaction, and the absorption of hydrogenation coral calcium can effectively reduce the level of inflammatory factor, disclose hydrogenationThe anti-inflammatory response effect of coral calcium.
The obesity that can effectively suppress high fat diet induction by above the results show hydrogenation coral calcium occurs, withIn time, can effectively be controlled and follows the fat metabolic disorder producing, and liver fat becomes and fat hepatitis. Proving by the same methods, with hydrogenation coralThe hydrogen molecule solid-state carrier that calcium has same class feature has same disease prevention and cure effect. In addition, hydrogen molecule structure is simple, neutralizationRadical reaction generates water, and potential side effect is less, and the hydrogen dissipating in body is breathed out by lung, less on homeostasis impact, machineBody better tolerance, has the market prospects of extensive use, opens up for preventing and treating the series of problems such as the obesity of diet structure due to unbalanceNew medical approach.
Claims (10)
1. the application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine, is characterized in that,
Obesity due to hydrogen molecule solid-state carrier is unbalance to diet structure has inhibitory action, described hydrogen molecule solid-state carrierBe taking the carbonate of calcium, magnesium as main the more than 50% of solid matter content that accounts for, form is Powdered, graininess, amorphous classThe solid-state form of type, this substance dissolves or be suspended in after liquid, can discharge the material of hydrogen molecule in solution, hydrogen in solutionContent is that 0.1ppm is above and below saturated concentration, can Scavenger of ROS free radical, and this material comprises but is not only hydrogenationCoral calcium.
2. application according to claim 1, is characterized in that, the inhibition that described hydrogen molecule solid-state carrier occurs obesity is doneWith effective absorption concentration range be per kilogram of body weight 10-50 milligram every day.
3. application according to claim 1, is characterized in that, described hydrogen molecule solid-state carrier can effectively improve fat sending outBody weight in raw process increases.
4. application according to claim 1, is characterized in that, described hydrogen molecule solid-state carrier can effectively improve fat sending outFat Accumulation in raw process.
5. application according to claim 1, is characterized in that, described hydrogen molecule solid-state carrier can effectively improve fat sending outThe generation of the disorders of lipid metabolism in raw process.
6. application according to claim 1, is characterized in that, described hydrogen molecule solid-state carrier can effectively improve fat sending outThe generation that liver fat in raw process becomes.
7. application according to claim 1, is characterized in that, described hydrogen molecule solid-state carrier can effectively improve fat sending outThe generation of the fat hepatitis in raw process.
8. application according to claim 5, is characterized in that, described hydrogen molecule solid-state carrier can effectively reduce in bloodContent of triglyceride.
9. application according to claim 6, is characterized in that, described hydrogen molecule solid-state carrier can effectively suppress in liverTriglycerides and the content of FFA.
10. application according to claim 7, is characterized in that, described hydrogen molecule solid-state carrier can effectively suppress liverIn inflammatory factor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410239813.6A CN104027350B (en) | 2014-05-30 | 2014-05-30 | The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410239813.6A CN104027350B (en) | 2014-05-30 | 2014-05-30 | The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104027350A CN104027350A (en) | 2014-09-10 |
| CN104027350B true CN104027350B (en) | 2016-05-04 |
Family
ID=51458495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410239813.6A Active CN104027350B (en) | 2014-05-30 | 2014-05-30 | The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104027350B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109489A (en) * | 2016-06-28 | 2016-11-16 | 西安交通大学 | The application in the medicine of the fat associated metabolic inflammation of preparation preventing and treating of the hydrogen molecule solid-state carrier |
| CN113908172A (en) * | 2021-12-01 | 2022-01-11 | 河北医科大学 | Application of hydrogen and calcium hydride coralline in preparing medicine for treating hyperpyrexia and mental disorder caused by methamphetamine |
| JP2024017521A (en) * | 2022-07-28 | 2024-02-08 | 国立研究開発法人国立成育医療研究センター | Fatty liver disease inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917913A (en) * | 1989-09-29 | 1990-04-17 | International Flavors & Fragrances Inc. | Use of sclareolide in augmenting or enhancing the organoleptic properties of foodstuffs |
| CN1833657A (en) * | 2005-03-16 | 2006-09-20 | 中国科学院地理科学与资源研究所 | Compound preparation for prevention and treatment adiposis and its prepn. method |
-
2014
- 2014-05-30 CN CN201410239813.6A patent/CN104027350B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917913A (en) * | 1989-09-29 | 1990-04-17 | International Flavors & Fragrances Inc. | Use of sclareolide in augmenting or enhancing the organoleptic properties of foodstuffs |
| CN1833657A (en) * | 2005-03-16 | 2006-09-20 | 中国科学院地理科学与资源研究所 | Compound preparation for prevention and treatment adiposis and its prepn. method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104027350A (en) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Quercetin has a protective effect on atherosclerosis via enhancement of autophagy in ApoE‑/‑mice | |
| CN104027350B (en) | The application of hydrogen molecule solid-state carrier in preparation inhibition fat health products and medicine | |
| CN101068559A (en) | Anti-hypersensitive inflammation and anti-allergy activities of zingiber zerumbet (L.) smith | |
| Wen et al. | Protective effect of pharmacological preconditioning of total flavones of abelmoschl manihot on cerebral ischemic reperfusion injury in rats | |
| CN103566198B (en) | Rhizoma Gastrodiae and gastrodine treat the application of the product of non-alcoholic fatty liver disease in preparation | |
| CN106109489A (en) | The application in the medicine of the fat associated metabolic inflammation of preparation preventing and treating of the hydrogen molecule solid-state carrier | |
| CN105435230A (en) | Application of O-GlcNAc glycosylation modification in preventing and treating hepatic fibrosis | |
| CN105982881A (en) | Application of bavachalcone and analogues thereof | |
| CN101732441B (en) | Extract of effective part of sibiraea augustata(rehd.) hand-mazz for preventing adiposity and lowering hyperlipoidemia, preparation method and application thereof | |
| TW201934740A (en) | Orange peel fermentation products and preparations and applications thereof | |
| Wu et al. | Taurine inhibits kupffer cells activation induced by lipopolysaccharide in alcoholic liver damaged rats | |
| CN102370738B (en) | Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof | |
| CN1569884B (en) | Method for preparing astragaloside and its use in preparation of drug for preventing and treating diabetic nephropathy | |
| CN103655997A (en) | Liver-soothing, brain-strengthening and depression-regulating tablet for treating post-stroke depression | |
| CN102475765A (en) | Traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis | |
| CN110420205A (en) | 3- hydroxyl -3 ', 4 '-dihydroxy-phenyl ethyl butyrate improve the application in aortic endothelial cell function medicament in preparation | |
| CN104688749A (en) | Ligustrum phenethyl alcohol glycoside composition for treating obesity and application thereof | |
| US20200368260A1 (en) | Use of benzopyran compound in preparation of product for regulating lipid metabolism and composition of the same | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN113082190A (en) | Application of cardiac mixture in preparation of medicine for blocking DCM through DCM myocardial cell autophagy mechanism | |
| CN101297827A (en) | Medicament for curing coronary disease and coronary artery coating bracket coated therewith | |
| CN104547388A (en) | Traditional Chinese medicine composition for treating alzheimer disease, as well as preparation method and application thereof | |
| CN104688800B (en) | Application of the total saponins from Cornus officinalis in the drug of preparation prevention and treatment diabetic complication | |
| CN109985206A (en) | For preventing and treating the composition of alcoholic liver injury | |
| TW202009009A (en) | Use of extract of artocarpus heterophyllus white core for regulating expression of cfos gene, csf1r gene, rank gene, syk gene, trap gene, apa1 gene, abca1 gene, il-6 gene, vcam1 gene, casp8 gene, ddc gene and asmtl protein gene, and improving menopausal syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171019 Address after: 201207 Shanghai City, Pudong New Area China (Shanghai) free trade zone fanchun Road No. 400 Building 1 floor 301-43 room 3 Patentee after: Shanghai Whole Life Biomedical Science and Technology Research Center (L.P.) Address before: 710049 Xianning Road, Shaanxi, China, No. 28, No. Patentee before: Xi'an Jiaotong University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220704 Address after: Room 404-29, 4th floor, building 2, No. 38, Debao Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai 200131 Patentee after: Shanghai Quanren Trading Co.,Ltd. Address before: 201207 room 301-43, floor 3, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee before: Shanghai Whole Life Biomedical Science and Technology Research Center (L.P.) |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221216 Address after: 200333 West, 1st Floor, Room 2, No. 14, 172zhi Lane, Lane 1340, Jinshajiang Road, Putuo District, Shanghai Patentee after: SHANGHAI RONGSHEN BIOCHEMICAL CO.,LTD. Address before: Room 404-29, 4th floor, building 2, No. 38, Debao Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai 200131 Patentee before: Shanghai Quanren Trading Co.,Ltd. |
|
| TR01 | Transfer of patent right |